-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27

Benzinga·05/22/2026 14:16:56
Listen to the news
B. Riley Securities analyst William Woods maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $40 to $27.